• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    山

    山形大学医学部附属病院

    Yamagata University Hospital
    EST. 1976
    874论文总数
    7,632引用总数

    论文量&引用量时间轴

    机构学者

    论文(874)

    年份
    起
    –
    止
    排序
    1Astrocyte Reactivity Across the AD Continuum Measured by [18F]SMBT-1 and Its Relationship with the Aβ Burden
    Yingying Wu,Kotaro Hiraoka, Berihu Mesfin,Asuka Kikuchi,Shoichi Watanuki,Shunji Mugikura,Naoki Tomita,Aiko Ishiki,Katsutoshi Furukawa,Yoshihito Funaki,Jun Toyohara,Yasuyuki Kimura,

    Astrocytes colocalize with fibrillar amyloid-β (Aβ) plaques in postmortem Alzheimer’s disease (AD) brain tissue; however, their spatiotemporal dynamics in vivo remain poorly understood. This multicenter study aimed to investigate the progression of astrocyte reactivity across the AD continuum, including healthy controls (HC), mild cognitive impairment (MCI), and AD, using the novel monoamine oxidase B (MAO-B)-specific PET tracer [18F]SMBT-1, while exploring its association with cognitive performance and amyloid burden. A total of 91 participants (35 HC, 44 MCI, 12 AD) underwent [18F]SMBT-1 PET, amyloid PET, T1-weighted MRI, and standardized neuropsychological assessments. Standardized uptake value ratios (SUVRs) were calculated based on [18F]SMBT-1 PET data using four reference regions for subgroup comparisons stratified by Aβ status. [18F]SMBT-1 uptake was significantly elevated in amyloid-positive MCI (MCI+) and AD groups compared with amyloid-negative HC (HC−) in the frontal, temporal, and posterior cingulate regions. Notably, astrogliosis patterns distinguished MCI subtypes: MCI+ individuals exhibited a widespread AD-like pattern, whereas the MCI− group showed a distinct profile. Furthermore, the uptake in symptomatic MCI+ individuals was significantly higher than that in asymptomatic HC+ individuals. Regional SMBT-1 uptake also strongly correlated with greater Aβ burden and worse cognitive scores. This study demonstrates that [18F]SMBT-1 is a promising tool for characterizing the spatial pattern and magnitude of reactive astrogliosis across the Aβ-defined AD continuum. Our findings further suggest that astrogliosis may represent an important mechanistic link between amyloid pathology and cognitive impairment, supporting its potential relevance in therapeutic development. Japan Registry of Clinical Trials (jRCT) jRCTs031210602, registered Feb. 07, 2022. https://jrct.mhlw.go.jp/en-latest-detail/jRCTs031210602 .

    2026European Journal of Nuclear Medicine and Molecular Imaging(2026)引用:43
    引用
    AI阅读
    加入学术空间
    2Clinical Outcome of 50 Patients Treated with Eribulin for Soft Tissue Sarcoma: a Single-Institute Retrospective Study.
    Yudai Murayama, Rumi Nakagawa, Yasutaka Sukawa,Masanobu Takahashi,Hiroyuki Kawashima,Kazutaka Kikuta

    BACKGROUND:Eribulin is an approved treatment option for soft tissue sarcomas (STSs) in Japan; however, real-world data regarding its safety, efficacy, and optimal dosing strategies across heterogeneous patient populations remain limited. Thus, this study aimed to evaluate clinical outcomes, treatment tolerability, and prognostic factors in patients with STS treated with eribulin. METHODS:We retrospectively reviewed 50 patients with STS who received eribulin at a single institution between 2018 and 2024. Clinical variables, dosing schedules, tumor responses, survival outcomes, and adverse events (AEs) were analyzed. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method; group comparisons were performed with the log-rank test. RESULTS:The cohort had a median age of 66 years, and eribulin was administered as first-line therapy in 24 patients. The disease control rate was 62%; one patient achieved complete response and one achieved partial response. Median PFS and OS were 4 and 19 months, respectively. Hematologic toxicities were the most common Grade ≥ 3 AEs, with no treatment-related cardiac events observed. Dose modifications included a bi-weekly schedule or a regimen consisting of two administrations followed by a 2-week rest period with pegfilgrastim support. No treatment discontinuations due to AEs occurred in either reduced-intensity schedule; the latter regimen demonstrated the longest treatment duration. Survival outcomes were comparable across age groups, treatment lines, histological subtypes, and tumor locations. Patients aged ≥70 years achieved a median OS of 16 months, generally consistent with previously reported outcomes in elderly sarcoma populations. CONCLUSIONS:Eribulin demonstrated favorable tolerability and durable disease control across diverse patient subgroups, including elderly and comorbid patients who are often ineligible for anthracycline therapy. Although no significant prognostic factors were identified, bi-weekly dosing and two-administration/2-week rest schedules were feasible, with the latter offering the advantage of pegfilgrastim support. These findings support the integration of eribulin into individualized treatment strategies for advanced STS and highlight the need for prospective studies to refine patient selection and optimize dosing approaches.

    2026Japanese journal of clinical oncology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Dependence of Motion Artifacts on the Starting Angle of Projection Data Collection in a Nonhelical Volume Scan of a 320-Row CT
    Yuho Kikuchi, Kazuhiro Sato, Toshimitsu Sato,Makoto Ohba,Koji Suzuki

    This study proposed a method to estimate the starting angle of projection data collection from streak motion artifact images using a clinical computed tomography scanner. Artifact images were obtained from projection data at different starting angles of collection using three different reconstruction methods (full reconstruction, half reconstruction, and Automatic Patient Motion Correction [APMC]) to identify reconstruction methods that are robust against motion artifacts. Data acquisition was performed using a 320-row CT. Motion artifact images were acquired in a nonhelical volume scan while moving the acrylic rod from the center of rotation to 12 o’clock. The amount of motion artifact was evaluated utilizing standard deviation obtained from a ring-shaped region of interest placed around the acrylic rod. Based on the direction of the artifacts, the proposed method could estimate the starting angle of collection with an accuracy of ± 5°; in the range of starting angles of collection of ± 20° at 12 o’clock and ± 20° at 6 o’clock, half reconstruction showed more severe motion artifacts than full reconstruction in some cases, increasing by up to approximately 61.7

    2026Physical and Engineering Sciences in Medicine(2026)
    引用
    AI阅读
    加入学术空间
    4Temporal Trends and Outcomes in Low-Risk Patients Undergoing TAVI: Insights from the LAPLACE-TAVI Registry
    Ryosuke Higuchi,Itaru Takamisawa,Mamoru Nanasato,Shinichiro Doi,Shinya Okazaki,Harutoshi Tamura, Masaki Ishiyama,Hiroaki Yokoyama,Motoki Fukutomi,Shuichiro Takanashi,Mike Saji,Mitsuaki Isobe

    BACKGROUND:Transcatheter aortic valve implantation is now indicated in low-risk patients following favorable outcomes in clinical trials and real-world registries. OBJECTIVES:The authors aimed to investigate temporal trends and long-term outcomes in this population. METHODS:Using a multicenter registry database (2010-2025), we stratified 5,691 patients by their Society of Thoracic Surgeons scores: low risk (<4%, n = 1,580 of 5,691 [27.8%]), intermediate risk (4% to 8%, n = 2,388 of 5,691 [42.0%]), and high risk (>8%, n = 1,723 of 5,691 [30.3%]). Low-risk patients were further classified according to clinical trial eligibility. The primary outcomes were crude 30-day and Kaplan-Meier-estimated 4-year all-cause mortalities. RESULTS:The annual procedure volume among low-risk patients did not show a sustained increase and declined after peaking in 2022. Low-risk patients were younger, predominantly male, had a higher body mass index (BMI), fewer comorbidities, and fewer procedural complications. They also demonstrated higher rates of elective procedure and transfemoral access. Thirty-day mortality and procedural complication rates remained consistently low among the low-risk cohort; furthermore, 4-year mortality was the lowest among trial-eligible low-risk patients (overall follow-up: 2.2 years). Clinical trial eligibility criteria (frailty [HR: 2.43; 95% CI: 1.43-4.14; P = 0.003] and renal dysfunction [HR: 3.00; 95% CI: 1.46-6.20; P = 0.010]), female sex (HR: 0.62; 95% CI: 0.44-0.89; P = 0.009), BMI (HR: 0.94 per kg/m2; 95% CI: 0.90-0.98; P = 0.008), and albumin levels (HR: 0.52 per g/dL; 95% CI: 0.36-0.77; P = 0.001) were associated with all-cause mortality in low-risk patients. CONCLUSIONS:Despite the overall expansion of transcatheter aortic valve implantation, procedure volume among low-risk patients has not consistently increased. Clinical trial eligibility, female sex, BMI, and albumin levels may refine risk stratification in Society of Thoracic Surgeons-defined low-risk patients. (Outcomes of transcatheter aortic valve implantation in Japanese patients with aortic stenosis: LAPLACE-TAVI registry; UMIN000031133).

    2026JACC Asia(2026)
    引用
    AI阅读
    加入学术空间
    5Model-Based Tacrolimus Dosing Using the Population Pharmacokinetic Analysis under the Nirmatrelvir/Ritonavir Therapy.
    Kotaro Itohara,Yoshiki Katada, Takahiro Hatayama, Toshiaki Igarashi,Jiro Ogura, Tomoki Fukushima,Shingo Yamazaki,Masato Homma,Takashi Niwa, Yoshiaki Kato,Nanae Yamamoto, Hideyuki Terazono,

    Nirmatrelvir/ritonavir is an antiviral agent used against severe acute respiratory syndrome coronavirus 2 infection and inhibits cytochrome P450 3A and P-glycoprotein. The concomitant use of nirmatrelvir/ritonavir markedly increases tacrolimus blood concentrations. Although temporary discontinuation or dose reduction of tacrolimus at the start of nirmatrelvir/ritonavir therapy is recommended in the package insert of this drug, little information is available on tacrolimus dosage adjustment when restarting. In this study, tacrolimus blood concentrations before and after nirmatrelvir/ritonavir co-administration were collected from national university hospitals across Japan, and population pharmacokinetic analysis was performed to develop an optimal dosing strategy for tacrolimus. In total, 83 tacrolimus blood concentrations from 15 patients were used in the analysis. First, the individual pharmacokinetic parameters of tacrolimus before the intake of nirmatrelvir/ritonavir were estimated by post hoc Bayesian analysis using previously reported population pharmacokinetic parameters based on a two-compartment model. The change in the relative bioavailability and clearance of tacrolimus after nirmatrelvir/ritonavir administration was estimated by population pharmacokinetic modeling. Consequently, tacrolimus clearance was considered almost completely inhibited, and relative bioavailability increased 7.99-fold with the co-administration of nirmatrelvir/ritonavir. The optimal dosing strategy based on the simulation was to withhold tacrolimus during nirmatrelvir/ritonavir therapy and to restart tacrolimus at 10% of the baseline dose on day 1, followed by 20% on day 3% and 50% on day 6, and increased to 100% on day 9 after discontinuation of nirmatrelvir/ritonavir, respectively. The proposed strategy will contribute to a safe and effective tacrolimus therapy when used in combination with nirmatrelvir/ritonavir.

    2026CPT pharmacometrics & systems pharmacology(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 874 篇论文

    合作机构(100)

    山形大学合作论文 133
    东北大学(日本)合作论文 84
    东京大学合作论文 43
    Tohoku University Hospital合作论文 37
    九州大学合作论文 34
    名古屋大学合作论文 28
    京都大学合作论文 23
    东邦大学合作论文 21
    新潟大学合作论文 19
    大阪大学合作论文 18

    机构统计